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Abstract 
The gastrointestinal microbiota colonize the digestive tract and are composed of 
approximately 1014 microbes and more than 400 species. These microbes are responsible 
for maintaining the gastrointestinal environment by facilitating digestion and interacting 
with the host immune system. In this study, the relationships among microbiota, their host 
and metabolites are analyzed from the viewpoint of molecular biology and public health. 
First, the effect of microbiota on atopic dermatitis is reviewed and analyzed. The results 
of a meta-analysis examining the effects of probiotics on children with atopic dermatitis 
make it difficult to conclude that probiotics have a suppressing effect on atomic dermatitis 
(AD) symptoms based on some qualified papers. Among these studies, the differences of 
patient age and country region produced the strongest effects on AD. On the other hand, 
it is difficult to discuss the effect of probiotics considering the differences in probiotics, 
as well as the differing dynamics of microbial profiles, which proved to be a major 
limitation of this study. Second, metabolic analysis and microbial population analysis of 
the murine intestinal tract components are conducted to understand the ecosystem among 
the host, metabolites and microbiota. Metabolic profiles have differences among each 
part of the intestine. Particularly, sugar shows the largest differences, and sugars are 
clustered into seven groups.  
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論文題目 
腸内細菌叢-代謝物間のマルチオミクス解析と小児アトピー性
皮膚炎プロバイオティクス効果のメタアナリシス 
 
 
論文要旨 
腸内細菌は腸内に生息しており、量にして 1014 個、400 種だと言われている。腸内環
境を維持するのにとても重要であると言われており、宿主の消化作用や免疫をサポ
ートしていると知られている。本研究では、腸内細菌を分子生物学と公衆衛生学の観
点から解析し、腸内細菌と代謝物、細菌間、宿主との相互作用について調べた。まず、
腸内細菌は小児アトピー性皮膚炎へのプロバイオティクス効果が期待されているの
で、宿主に対してどのような効果があるのかを解析した。小児アトピー性皮膚炎患者
に対するプロバイオティクスのメタアナリシスの結果、本研究で扱ったいくつかの論文
の場合には、プロバイオティクスの維持・改善効果があるとは言えないことを示した。
本研究のリミテーションは、使用した論文の臨床試験の対象者の年齢や実施国、さら
には投与した菌種が異なるため、一様に議論を行うことが難しい。また、次に SPF マ
ウスと GF マウスの腸管を用いた部位別のメタボローム解析と細菌叢解析を行い、腸
内のエコシステム内でどのような代謝物と細菌が存在するのか解析した。結果、メタ
ボローム解析では、腸管の部位ごとに代謝物のプロファイルが大きく異なることを示
した。大きく変化していたアミノ酸のと糖のプロファイルを観察したところ、アミノ酸のプ
ロファイルは部位ごとに大きな変化はなく、ほとんどのアミノ酸が同じ挙動を示した。
一方で、糖のプロファイルは、糖のサイズによって部位ごとに濃度が大きく変化してい
ることが分かった。 
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Chapter 1 
1. Introduction 
1.1. Relationship between humans and bacteria 
Bacteria are relevant and important to human life. Animals and plants coexist with 
bacteria in various ways. Animals retain bacteria on their skin to maintain the skin 
environment and within the intestinal tract for obtaining secondary metabolites such 
as vitamins (Figure 1.1). In addition, humans produce fermented food and drinks such 
as yogurt, miso, cheese, kimchi, wine and Japanese sake. The intestinal microbiota are 
a research target particularly in relation to the immune system and health. Some 
bacteria have functions in the management of the intestinal tract. The function is 
dependent on probiotics, prebiotics, and synbiotics. The most notable definition of 
probiotics is, “a live microbial feed supplement which beneficially affects the host 
animal by improving its intestinal microbial balance,” defined by Fuller (Fuller, 1989). 
Another notable definition states, “live micro-organisms which, when administered in 
adequate amounts, confer a health beneﬁt on the host” as defined by FAO/WHO 
(Group, 2002). Two widely known terms that are also related to probiotics are 
prebiotics and synbiotics (Schrezenmeir and de Vrese, 2001). One definition of 
1.Introduction 
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prebiotics states, “a non-digestible food ingredient that beneficially affects the host by 
selectively stimulating the growth and/or activity of one or a limited number of 
bacteria in the colon” (Gibson and Roberfroid, 1995). Synbiotics is known as the 
mixture of probiotics and prebiotics.  
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Figure 1.1 The area of bacteria living 
This figure show the area of human body where microbiota live. Large circles: Bacteria, Small 
circle right: Fungi, Small circles left: Viruses (Marsland and Gollwitzer, 2014) 
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1.2. Objective 
As microbiota function, they have a relationship with the host through metabolites. In 
this study, the relationships among microbiota, their host and metabolites are analyzed 
from the viewpoint of molecular biology and public health to understand the effect of 
intestinal microbiota. In the first section, a systematic review and meta-analysis of the 
effect of probiotics on children with atopic dermatitis (AD) is conducted. The purpose 
of this systematic review and meta-analysis is to determine the effects of probiotics on 
AD children. In the second research study, a luminal metabolic evaluation for each 
part of the intestinal tract is performed to understand the differences among them. We 
measured the gastrointestinal luminal metabolites across different parts of the 
intestinal tract in specific-pathogen-free (SPF) and germ-free (GF) mice by using 
capillary electrophoresis time-of-flight mass spectrometry (CE-TOFMS) and liquid 
chromatography-tandem mass spectrometry (LC-MS/MS). The final research study 
aims to apply the previous study’s method (Stein et al., 2013) to this experimental data 
to understand the relationship between bacteria. 
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Chapter 2 
2. The effects of probiotics on children with 
atopic dermatitis 
2.1. Introduction 
2.1.1. Atopic dermatitis 
Atopic dermatitis (AD) is one of the most pervasive chronic allergic diseases with 
itching and redness (Kay et al., 1994). One of the features of this disease is that its 
prevalence in children is higher than that of adults. It is known that up to 10–20% of 
children and 1-3% of adults have AD in Europe (Leung and Bieber, 2003). Although 
many causes have been speculated for AD, including genetic factors, environmental 
factors, nutrition and intestinal microbiota, the mechanism of this disease is still 
unclear. As a genetic factor, it has been reported that the genetic mutation of filaggrin 
may cause the underlying symptoms of AD, while reducing the barrier function of the 
skin (Hoffjan and Stemmler, 2015). Filaggrin is an essential protein for skin barrier 
function, in particular, the formation of a horny layer. When the skin barrier becomes 
weak due to a mutation on a gene coding filaggrin, the environment is also important 
factor for inducing stimulation. Dysbiosis, a microbial imbalance on our body, is said 
2.The effects of probiotics on children with atopic dermatitis 
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to be one of the causes of AD. Intestinal microbiota are bacteria that live inside animal 
intestinal tracts, and support the host’s digestive function, and provide nutrition by 
producing secondary metabolites, as well as maintaining the homeostasis of the host’s 
intestinal tract (Holmes et al., 2012). Additionally, it became clear that there are 
relationships between intestinal microbiota and some diseases, including AD 
(Björkstén et al., 1999; 2001; Kalliomäki et al., 2001).  
 
2.1.2. SCORAD 
The primary outcome was the change of SCORAD index (STALDER and TAIEB, 
1993) from baseline to post-treatment. SCORAD, which was evaluated by 10 trained 
clinicians, is the major index for evaluating AD symptoms (Figure 2.1). The worst 
symptom corresponds to 103 points, and this score is evaluated from by extent, 
intensity and subjective. The severity of symptom is categorized into six fields: 
erythema, edema/papulation, oozing/crusts, excoriations, lichenification, and dryness. 
Considering the characteristic of AD symptom, the score weighting is different 
between under/over two years. 
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2.1.3. Probiotics, prebiotics, and synbiotics 
Microbiota is used as probiotics for improving our health. The most notable definition 
of probiotics is, “a live microbial feed supplement which beneficially affects the host 
animal by improving its intestinal microbial balance,” defined by Fuller (Fuller, 1989). 
Another notable definition states, “live micro-organisms which, when administered in 
adequate amounts, confer a health beneﬁt on the host” as defined by FAO/WHO 
(Group, 2002). Two widely known terms that are also related to probiotics are 
prebiotics and synbiotics (Schrezenmeir and de Vrese, 2001). One definition of 
prebiotics states, “a non-digestible food ingredient that beneficially affects the host by 
selectively stimulating the growth and/or activity of one or a limited number of 
bacteria in the colon” (Gibson and Roberfroid, 1995). Synbiotics is known as the 
mixture of probiotics and prebiotics. 
 
2.1.4. Systematic review 
For a given research target, a variety of approaches and techniques are used for 
investigation; however, the quality of researches is dependent upon the study design. 
In the epidemiology field, two types of observational study, case-control study and 
cohort study, are mainly used. Case-control study identifies factors that may contribute 
2.The effects of probiotics on children with atopic dermatitis 
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to a medical condition by comparing groups differing in outcome, retrospectively. On 
the other hand, cohort study compares outcome of two groups differing in condition 
by following them for a certain period of time. In addition to these designs, there is 
other kind of study known as intervention study. This study has two methods, 
nonrandomized and randomized control trials (RCT). A randomized control trial 
produces more quality data considering its lack of subject bias. 
 Furthermore, systematic review is one of the highest quality research methods 
used to collect and examine research data. Systematic review is different from 
conventional reviews at the point that evaluation is systematically conducted. 
Systematic review is an essential process of evidence-based medicine. The method for 
integrating this data and evaluating the result is called meta-analysis (Sacks et al., 
1987). Meta-analysis enables to overcome the problem of subject size and the obstacle 
of bias among clinical trials. Summarizing the relation between outcomes of clinical 
trials related to AD children and probiotics is important for understanding the effect 
of probiotics and their mechanisms. Recently, Kim reported a meta-analysis for the 
relationship between AD and the effect of probiotics (Kim et al., 2014). They 
conducted a comprehensive study, from infant to adult, considering the AD severity 
and patient age. As a result, they concluded that probiotics were effective for 
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moderating severe AD in patients of all ages. However, as the interaction with the host 
intestinal environment was not considered, the children and home country were 
focused on in order to take into account the diversity of host intestinal microbiota. The 
children’s profiles have less diversity than the adults’ profiles (Kostic et al., 2013). 
The purpose of this systematic review and meta-analysis was to determine the effects 
of probiotics on AD children. 
 
2.2. Methods 
2.2.1. Investigated papers 
PubMed and Cochrane Library were searched in June of 2015 with the following 
keywords: “Dermatitis, Atopic”[Mesh] OR atopic dermatitis AND 
“Probiotics”[Mesh], OR “Lactobacillus”[Mesh], OR “Bifidobacteriales 
Infections”[Mesh], OR “Lactococcus”[Mesh], OR “Saccharomyces ” [Mesh], OR 
“ Streptococcus thermophilus ” [Mesh], OR “ Bacillus Subtilis ” [Mesh], OR 
“Enterococcus faecalis”[Mesh], OR “Clostridium”[Mesh]．The type of article was 
filtered to include only Randomized control trials. After a systematic search, a manual 
search was conducted. Included (1) articles of the RCT type, (2) patients of age (< 10 
years) with AD, (3) cases with intervention conducted by using probiotics, (4) articles 
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written in English. Excluded (1) cases in which intervention was conducted by using 
prebiotics or synbiotics, (2) cases in which the main target was an allergy such as food 
allergy. WHO’s definition of probiotics was used for this study, and if indigestible 
sugar or fibers were included as part of the intervention, these were regarded as 
prebiotics. Before conducting the meta-analysis, the article qualities were checked 
using CONSORT (Moher et al., 2010)(Table 2.1) to compare the quality of the RCTs. 
The nine studies that satisfied these requirements included crossover trials. When the 
quality of an article is checked, CONSORT does not accept crossover trials; however, 
CONSORT was used because the checklist for crossover trials has not yet published. 
 
2.2.2. Statistical Analysis 
The primary outcome was the change of SCORAD index (STALDER and TAIEB, 
1993) from baseline to post-treatment. SCORAD index is the major index for 
evaluating AD symptoms (Figure 2.1). A small index size indicated that the symptom 
was mild, and a large index size indicated that the symptom was severe. In order to 
combine the results from these RCTs, the standard deviation (S.D.) of each study was 
calculated and incorporated. The requirement of this research was written as the 
average and S.D. or standard error (S.E.) of SCORAD from baseline to after treatment 
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in both group control and intervention. Data syntheses were based upon, either the 
fixed or the random effect model, according to the extent of heterogeneity (p-value of 
Cochrane Q-test < 0.05). All of the statistical analyses were performed by R 3.1.2 (R 
Foundation for Statistical Computing, Vienna, Austria. http://www.r-
project.org/index.html). A two sided p-value < 0.05 was set as the significant level. 
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Table 2.1 Checklist of CONSORT 
 
  
!"#
!"#$%&'(&)*+,%-'!"#$%&'!"#$!" !"#!! !"#"
表　ランダム化比較試験を報告する際に含まれるべき情報のCONSORT 2010チェックリスト＊
CONSORT 2010 checklist of information to include when reporting a randomized trial
＊本声明は，各項目についての重要な解説を記載したCONSORT 2010解説と詳細13）とともに用いることを強く推奨する。クラスターラン
ダム化比較試験11），非劣性・同等性試験12），非薬理学的治療 32），ハーブ療法 33），実用的試験 34）については，CONSORT声明拡張版を推
奨する。そのほかの拡張版も近日発表予定（それらと本チェックリスト関連の最新情報はwww.consort-statement.orgを参照）。
                章／トピック
            （Section/Topic）
 
タイトル・抄録
（Title and Abstract）
 
 
はじめに（Introduction）
　背景・目的
　（Background and Objective）
 
方法（Method）
　試験デザイン（Trial Design）
　
　参加者（Participant）
　
　介入（Intervention）
　アウトカム（Outcome）
　
　症例数（Sample size）
　
　ランダム化（Randomization）
　　順番の作成
　　（Sequence generation）
　　　割振りの隠蔵機構
　　（Allocation concealment 
        　mechanism）
　　実施（Implementation）
　ブラインディング（Blinding）
　
　統計学的手法
　（Statistical method）
 　
結果（Results）
 　参加者の流れ
　（Participant flow）
　（フローチャ トーを強く推奨）
 　募集（Recruitment）
 
 　ベースライン・データ
　（Baseline data）
 　解析された人数
　（Number analyzed）
 　アウトカムと推定
　（Outcome and estimation）
 
 　補助的解析
　（Ancillary analysis）
 　害（Harm）
 
考察（Discussion）
 　限界（Limitation）
 　一般化可能（Generalisability）
 　解釈（Interpretation）
 
その他の情報
 （Other information）
 　登録（Registration）
 　プロトコール（Protocol）
 　資金提供者（Funding）
  項目番号
（Item No）
 
　   1a　
 　   1b　
 　
 
　   2a
　
   2b
　
　
   3a
　
   3b
　
   4a
　
   4b
　
   5
　
   6a
　
   6b
　
   7a
　
   7b
　
　
   8a
　
   8b
　
   9
　
 10
 　 11a
　
　 11b
　
 12a
　
 12b
 
　 13a
 　 13b
 　 14a
 　 14b
 　 15
 　 16
 　 17a
 　 17b
 　 18
 
　 19
 
　
 20
 　 21
 　 22
 　
 　 23
　
 24
　
 25
                                                                 　　 チェックリスト項目
                                                                          （Checklist Item）
 
タイトルにランダム化比較試験であることを記載。
試験デザイン（trial design）， 方法（method）， 結果（result）， 結論（conclusion）の構造化抄録（詳細は 「雑誌およ
び会議録でのランダム化試験の抄録に対するCONSORT声明」 21, 31）を参照）。
 　
科学的背景と論拠（rationale）の説明。
　特定の目的または仮説（hypothesis）。
 
 試験デザインの記述（並行群間，要因分析など）， 割付け比を含む。
　試験開始後の方法上の重要な変更（適格基準 eligibility criteria など）とその理由。
　参加者の適格基準（eligibility criteria）。
　データが収集されたセッティング（setting）と場所。
　再現可能となるような詳細な各群の介入。 実際にいつどのように実施されたかを含む。
　事前に特定され明確に定義された主要・副次的アウトカム評価項目。 いつどのように評価されたかを含む。
　試験開始後のアウトカムの変更とその理由。
　どのように目標症例数が決められたか。
　あてはまる場合には， 中間解析と中止基準の説明。
　　
　割振り（allocation）順番を作成（generate）した方法。
　割振りのタイプ : 制限の詳細（ブロック化，ブロックサイズなど）。
　ランダム割振り順番の実施に用いられた機構（番号付き容器など）， 各群の割付けが終了するまで割振り順番が
隠蔵されていたかどうかの記述。
　誰が割振り順番を作成したか， 誰が参加者を組入れ（enrollment）たか， 誰が参加者を各群に割付けた（assign）か。
　ブラインド化されていた場合， 介入に割付け後，誰がどのようにブラインドかされていたか（参加者， 介入実施者，
アウトカムの評価者など）。
　関連する場合， 介入の類似性の記述。
　主要・副次的アウトカムの群間比較に用いられた統計学的手法。
　サブグル プー解析や調整解析のような追加的解析の手法。
　
各群について， ランダム割付けされた人数， 意図された治療を受けた人数， 主要アウトカムの解析に用いられた
人数の記述。
 各群について， 追跡不能例とランダム化後の除外例を理由とともに記述。
 参加者の募集期間と追跡期間を特定する日付。
 試験が終了または中止した理由。
 各群のベースラインにおける人口統計学的（demographic）， 臨床的な特性を示す表。
 各群について， 各解析における参加者数（分母）， 解析が元の割付け群によるものであるか。
 主要・副次的アウトカムのそれぞれについて， 各群の結果， 介入のエフェクト・サイズの推定とその精度（95％信
頼区間など）。
 
 2項アウトカムについては， 絶対エフェクト・サイズと相対エフェクト・サイズの両方を記載することが推奨される。
 サブグル プー解析や調整解析を含む， 実施した他の解析の結果。 事前に特定された解析と探索的解析を区別する。
 
各群のすべての重要な害（harm）または意図しない効果（詳細は 「ランダム化試験における害のよりよい報告 :  
CONSORT声明の拡張」 28）を参照）。
　
 試験の限界， 可能性のあるバイアスや精度低下の原因， 関連する場合は解析の多重性の原因を記載。
 試験結果の一般化可能性（外的妥当性， 適用性）。
 結果の解釈， 有益性と有害性のバランス， 他の関連するエビデンス。
 　
　登録番号と試験登録名。
　可能であれば， 完全なプロトコールの入手方法。
　資金提供者と他の支援者（薬剤の供給者など）， 資金提供者の役割。
                       報告頁
（Reported on page No）
2.The effects of probiotics on children with atopic dermatitis 
13 
 
Figure 2.1 Evaluation sheet for SCORAD 
Symptom of AD is evaluated conforming to this evaluation sheet (original figure from Stalder et 
al., 1993). 
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2.3. Results 
Sixty-four trials were identified in total from PubMed and Cochrane Library, and nine 
RCTs were included in the meta-analysis (Figure 2.2, Supplementary List 1: 
http://tinyurl.com/znrpexg）. 2 studies not written in English were excluded, 4 studies 
that were not original papers and 27 studies that differed from our purpose. Finally, 24 
studies were separated into three groups, infant and mother, child, and adult. Thirteen 
studies categorized into the child group included 2 studies focused on infants. It is 
known that the profile of intestinal microbiota differs between neonates and infants, 
so 2 studies were excluded from the child group. Additionally, the outcome of 2 studies 
did not employ the SCORAD index. Although a hand search was performed for 
references from these nine articles, no articles satisfied the requirement 
(Supplementary List 2: http://tinyurl.com/hmgmjm5). 
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Figure 2.2 Flow diagram of the process of selecting relevant trials 
In total, 64 articles were satisfactory using these keywords at the first review. 
  
2.The effects of probiotics on children with atopic dermatitis 
16 
 The summary of these 9 studies is shown in Table 2.2. The maximum and 
minimum intervention terms were six months and six weeks, respectively. There were 
two types of interventions, powder and capsule. When prescribed the powder, the 
amount and type of liquid were limited. Thirteen species of intestinal microbiota were 
used as probiotics. Probiotics were composed of one specific species of bacteria in five 
studies and two species of bacteria in four other studies. Bacteria from the 
Lactobacillus genus were used as probiotics in all the nine studies. The most frequently 
used bacteria in these studies were the Lactobacillus rhamnosus strain GG (LGG). The 
minimum amount of bacteria was 1×109 Count-Forming Units (CFU), twice a day, 
and the maximum amount of bacteria was 2×1010 CFU / g once a day. In these studies, 
allergy existence was also considered as baseline data, along with personal data. As 
usual, a steroid was used as a main treatment. Although the amount of steroid was 
limited, steroid uses in these studies were permitted. Within these nine studies, four 
studies showed improvement of the symptom outcome, and the other five studies 
showed no improvement. In addition, the four studies showing the effects of probiotics 
were focused on children > 6 months. 
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Table 2.2 Evidence table of review 
 
Outcome A: molecular outcome, B: microbial outcome，C: Symptom outcome. W: written, I: 
ineffective, E: effective 
Molecular outcome represented as amount of IgA. Microbial outcome included amount of 
microbial population. Symptom outcome included SCORAD index. 
  
Article Study size Duration Proviotics Amount
Intervention 
term 
(weeks)
Follow up 
(weeks)
Outcome
A B C
1 Fölster-Holst et al 2006 n = 53 1-55 months Lactobacillus rhamnosus strain GG 5×10
9CFU, twice/day 8 4 W I
2 Gore et al 2011 n = 208 3-6 months
Lactobacillus paracasei CNCM I-2116 
Bifidobacterium lactis CNCM I-3446 1×10
10CFU,  everyday 12 3 years W I
3 Nermes et al 2010 n = 39 2.2-13 months Lactobacillus rhamnosus strain GG ATCC 53103 3.4×10
9CFU,  everyday 12 - W W I
4 Weston et al 2005 n = 56 6-18 months Lactobacillus fermentum VRI-033 PCC 1×10
9CFU, twice/day 8 8 W E
5 Rose et al 2010 n = 121 6-24 months Lactobacillus rhamnosus strain GG ATCC 53103 1×10
10CFU, twice/day 6 6 W I
6 Larsen et al 2011 n = 50 7-24 months
Lactobacillus acidophilus NCFM ATCC SD5220 
Bifidobacterium animalis subsp. lactis Bi-07 1×10
10CFU,  everyday 8 - W E
7 Sistek et al 2006 n = 59 1-10 years
Lactobacillus rhamnosus 
Bifidobacteria lactis Total 2×10
10CFU/g,  everyday 12 4 E
8 Han et al 2012 n = 118 1-13 years Lactobacillus plantarum CJLP133 5×10
9CFU, twice/day 16 2 W E
9 Rosenfeldt et al 2004 n = 43 1-13 years
Lactobacillus rhamnosus 19070-2 
Lactobacillus reuteri DSM 12246 1×10
10CFU, twice/day 8 8 W I
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 After screening, an evaluation on the quality of RCTs was conducted (Table 
2.3). Only five studies within the nine studies estimated the 95% confidence interval 
(CI) within the SCORAD index. Weston’s study reported statistic results and baseline 
data separately; therefore, these two reports were used for evaluation. As a result, no 
studies significantly lacked the necessary data. For this reason, sub-group analysis was 
not conducted in this study. 
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Table 2.3 CONSORT checklists for evaluating studies’ quality 
  
Check list  1 2 3 4 5 6 7 8 9 
Title, 
abstract 
Title 1a Y n.r. Y n.r. n.r. n.r. I Y n.r. 
Abstract 1b Y Y Y Y n.r. Y Y Y Y 
Introduction 
Background 2a Y Y Y Y Y Y Y Y Y 
Objectives 2b Y Y Y Y Y Y Y Y Y 
Methods 
Trial Design 3a Y Y Y I Y I Y Y Y 
Changes to trial design 3b - - - - - - - - - 
Participants 4a Y Y Y Y n.r. Y Y Y Y 
Study settings 4b n.r. n.r. n.r. Y Y n.r. n.r. n.r. n.r. 
Interventions 5 Y Y Y Y Y Y Y Y Y 
Outcomes 6a Y I Y Y I I Y Y Y 
Changes to outcomes 6b - - - - - - - - - 
Sample size 7a Y n.r. n.r. Y n.r. Y Y Y Y 
Interim analyses and 
stopping guidelines 7b - - - - - - - - - 
Randomisation: sequence 
generation 8a n.r. n.r. n.r. n.r. n.r. Y n.r. n.r. n.r. 
Randomization: type 8b Y n.r. n.r. n.r. n.r. n.r. n.r. Y Y 
Randomisation: allocation 
concealment mechanism 9 n.r. n.r. n.r. n.r. n.r. n.r. Y n.r. n.r. 
Randomisation: 
implementation 10 n.r. n.r. n.r. n.r. n.r. n.r. Y n.r. n.r. 
Blinding 11a Y Y Y Y n.r. Y Y Y Y 
Similarity of interventions 11b n.r. n.r. n.r. n.r. n.r. n.r. n.r. n.r. n.r. 
Statistical methods 12a Y Y Y Y Y n.r. Y Y Y 
Additional analyses 12b Y - - - - - - - - 
Result 
Participant Flow 13a Y Y Y Y n.r. Y Y Y Y 
Losses and exclusions 13b Y Y Y Y n.r. Y Y Y Y 
Recruitment 14a n.r. n.r. I I n.r. I n.r. I I 
Reason for stopped trial 14b n.r. Y n.r. n.r. n.r. n.r. n.r. n.r. n.r. 
Baseline Data 15 n.r. Y Y Y n.r. Y Y Y Y 
Numbers analyzed 16 Y Y Y Y Y Y Y Y Y 
Outcomes and estimation 17a Y Y Y Y I Y I Y Y 
Binary outcomes 17b - - I Y - Y - - Y 
Ancillary analyses 18 - - - - - - - - - 
Harms 19 n.r. n.r. Y n.r. n.r. n.r. n.r. n.r. n.r. 
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Y: Written, I: Written partially, n.r.: Not reported, -: Not reported (not necessary) 
1-9: Corresponded to the article’s number from Table 2.2 
  
Discussion 
Limitations 20 Y n.r. Y Y Y Y n.r. n.r. Y 
Generalizability 21 Y Y Y Y n.r. n.r. n.r. Y Y 
Interpretation 22 Y Y Y Y Y Y Y Y Y 
Other 
information 
Registration 23 Y Y n.r. Y n.r. n.r. Y n.r. n.r. 
Protocol 24 n.r. n.r. n.r. n.r. n.r. n.r. n.r. n.r. n.r. 
Funding 25 Y Y Y Y Y Y Y Y Y 
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 Although the nine studies were included for evaluation, only five studies were 
used for meta-analysis (Table 2.4, Figure 2.3A) due to the limitation of statistical data. 
Four studies were not sufficiently significant to mention the results of their SCORAD 
index. Figure 2.3 shows the results of meta-analysis based on the changes of SCORAD 
index. Although heterogeneity was large in a randomized effect model, meta-analysis 
of entire studies did not show a significant decrease in the SCORAD index within the 
probiotics group compared to that within the control group (estimator: -0.27, 95% CI: 
-3.69 to 3.15, p = 0.88; Table 2.5, Figure 2.3A). This 95% CI was extended across 0; 
therefore, the effect of probiotics was not observed in this meta-analysis. Additionally, 
Han’s study was the only study showing the effects of probiotics for AD, and there 
were no commonalities between other studies in terms of probiotics type, intervention 
term, or patients. 
 Next, sub-group analysis was conducted by age group. These nine studies 
were separated by the patients age, which was six months (Figure 2.3B)．The 
heterogeneity of studies that focused on children < 6 months was small (p = 0.96). As 
the result of sub-group analysis, the estimator of SCORAD was 2.01 (95% CI: 0.89 to 
3.13, p < 0.001; Table 2.5, Figure 2.3B) and the effects of probiotics in increasing the 
index are shown. The heterogeneity of studies that focused on children > 6 months 
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was large (p < 0.001). As the result of sub-group analysis, the estimator of SCORAD 
was -2.04 (95% CI: - 6.06 to 1.99, p = 0.32; Table 2.5, Figure 2.3C) and the effects of 
probiotics in decreasing the index are shown (Figure 2.3C). 95% CI was extended 
across 0; therefore, the effects of probiotics were not shown in this sub-group analysis. 
 As the other sub-group analysis, the patient’s country of origin was focused 
on. In this analysis, it was found that the studies conducted in Europe showed a similar 
result among each trial (Figure 2.3D). The heterogeneity of the sub-group analysis was 
not significant (p = 0.14). As the result of sub-group analysis, the estimator of 
SCORAD was 1.53 (95% CI: 0.60 to 2.47, p < 0.001; Table 2.5, Figure 2.3D) and the 
effects of probiotics in significantly increasing the index were shown. As the result of 
these sub-group analyses, the common factor toward showing large heterogeneity 
came from including Han and Sistek’s studies 
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Table 2.4 Studies included in meta-analysis 
 
  
Article(Year) Studysize Duration Country Proviotics Amount
Intervention 
term
(weeks)
Follow up
Outcome
A B C
1 Fölster-Holst et al(2006) n = 53 1-55 months Germany Lactobacillus rhamnosus strain GG 5×10
9CFU, twice/day 8 4 weeks W I
2 Gore et al
(2011) n = 208 3-6 months England
Lactobacillus paracasei CNCM I-2116
Bifidobacterium lactis CNCM I-3446 1×10
10CFU,  everyday 12 3 years W I
3
4
Larsen et al
(2011) n = 50 7-24 months Denmark
Lactobacillus acidophilus NCFM ATCC SD5220
Bifidobacterium animalis subsp. lactis Bi-07 1×10
10CFU,  everyday 8 - W E
5
6 Sistek et al(2006) n = 59 1-10 years New Zealand
Lactobacillus rhamnosus
Bifidobacteria lactis Total 2×10
10CFU/g,  everyday 12 4 weeks E
7 Han et al(2012) n = 118 1-13 years Korea Lactobacillus plantarum CJLP133 5×10
9CFU, twice/day 16 2 weeks W E
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Figure 2.3 Includes the forest plots and statistics of shifts of SCORAD 
A-D: Left side means negative and right side means positive. The horizontal axis shows the 
estimator of changes of SCORAD index mean and the box size depends on the size of population. 
Dotted line indicates the estimator of statistical model. (A) All, (B) < 6months, (C) > 6 months, 
(D) Europe. 
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Table 2.5 Estimator of changes of SCORAD index mean 
 Object Included trial numbers F/R 
Estimator 
(P-value) 
95% CI 
(Estimator) 
Heterogeneity 
P-value 
A All 7 R -0.27 (P = 0.88) - 3.69 / 3.15 < 0.001 
B < 6 months 3 F 2.01 (P < 0.001) 0.89 / 3.13 0.96 
C > 6 months 4 R -2.04 (P = 0.32) - 6.06 / 1.99 < 0.001 
D Europe 5 F 1.5341 (P = 0.001) 0.60 / 2.47 0.14 
F: Fixed effect, R: Random effect 
A-D: Corresponded to the sub-group’s number from Figure 2.3. 
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2.4. Discussion 
In this study, meta-analyses was conducted and reviewed papers included five trials 
considering age and country region. Five trials conducted in Europe were gathered as 
one sub-group. The result of the sub-group analysis showed that the symptoms became 
worse when the European AD children took probiotics. The heterogeneity of these 
data was large and 95% CI was extended across 0, even when using a randomized 
effect model. This result suggests that it is difficult to conclude if the probiotics had 
an effect on AD children, as this result is consistent with Kim’s previous research (Kim 
et al., 2014). Björkstén reported that the amount of Enterococcus and Bifidobacterium 
was significantly small between one-month-old and one-year-old AD children’s 
intestinal tract (Björkstén et al., 2001), as it is said that probiotics rearrange the profiles 
of intestinal microbiota and suppress symptoms. Although the method of treatment 
was discussed, the effect was not clearly shown in the case of AD. There remains 
causal ambiguity, as many reports and books do not refer to the effect of probiotics for 
AD, and the effects were dependent on each clinical trial (Van Der Aa et al., 2010)．
The reasons for variation in the effects of bacteria on patients were thought to 
dependent on patient age, gender, race, life style, original profiles of intestinal 
microbiota, amount of probiotics, kinds of species, and the clinical trial design. The 
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features of intestinal microbiota were dependent on kinds and strains, which served to 
produce the disparity in data regarding the effect of these microbiota. 
 LGG, used in many reports, was bacillus and produced lactate. It was reported 
to give benefits for hosts and resistance to stomach acid and bile acid. Unfortunately, 
the trials that used LGG had the following three results: probiotics had effects, no 
effects were observed, and unclear. Therefore, LGG’s effects as probiotics are still 
unclear. In addition, some trials did not refer to the strain of bacteria, and because the 
species were different among these trials, it is difficult to discuss the effect of the 
probiotics. 
Sub-analysis was conducted according to the patient’s age and country, which 
were thought to be a cause of heterogeneity. In the case of sub-group analysis including 
trials with patient age < 6 months, the changes in SCORAD index increased. This 
suggested that the probiotics did not have the effect of suppressing the AD symptoms, 
as AD became worse. In the case of sub-group analysis including trials with object age 
> 6 months, the heterogeneity was small and the changes in SCORAD index did not 
increase. This suggested that probiotics had the effect of suppressing the AD 
symptoms, as AD did not become worse. The clinical use of probiotics is defined as 
intake of bacteria known to benefit us, and the effects of probiotics were thought to 
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depend on the host intestinal environment and immune system. It is known that the 
host microbial profiles change relative to the host age, and it was reported that aerobic 
bacteria increased first, followed by anaerobic bacteria that increased through oxygen 
consumption, as reported by the study focused on the host’s growth (Turroni et al., 
2012)．  Smith reported that microbial patterns were almost the same and not 
dependent on the host animal (Smith, 1965)． 
 Additionally, the result of sub-group analysis considering the patient’s 
country showed that the heterogeneity was small. The changes in SCORAD index 
increased. Comparing the heterogeneity of meta-analysis including whole trials and 
sub-analysis by considering the country, the size of heterogeneity decreased. This sub-
group segmentation, which considered patient country regions, was different from 
Kim’s research, and suggested that the country regions are a possible factor in 
changing the size of heterogeneity. Considering the results of the sub-group analysis, 
it seems that one of the causes for effects of bacteria on patients was the host intestinal 
environment. There were already some reports focused on the relationship among the 
microbial profiles, diet, and country, and the intestinal microbial profiles were divided 
into three types and the differences were dependent on the diet (Arumugam et al., 
2011). It may also be noted that Japanese intestinal microbiota have a potential to 
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digest seaweed such as laver (Hehemann et al., 2010)．The country region and race 
are important factors in understanding the details of systems related to intestinal 
microbiota. 
 There were some similarities within the large heterogeneity. For example, 
when data were integrated and the heterogeneity was large, studies by Han and Sistek 
were included for analysis. From this result, it was suggested that these two trials most 
directly affected the size of heterogeneity. These two trials were difficult to integrate 
because there were many discrepancies in the data, because the reliability was low, as 
the countries in which the trials were performed were Korea and New Zealand. 
Lactobacillus plantarum CJLP133, used in Han’s study, was isolated from Kimchi and 
suggested to control the immune system (Lee et al., 2011). In addition, this strain was 
also reported to have the effect of suppressing AD in an AD mouse by oral intervention 
(Won et al., 2011). This strain also demonstrated the effect of curing dermatitis-like 
AD by inducing house dust and mites on an NC/Nga mouse (Won et al., 2012)． 
 In summary, clinical trials that focused on the effects of probiotics on infant 
AD were screened systematically. Among these studies, the differences of patient age 
and country region produced the strongest effects on AD. On the other hand, it is 
difficult to discuss the effect of probiotics considering the differences in probiotics, as 
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well as the differing dynamics of microbial profiles, which proved to be a major 
limitation of this study. As the number of trials using the same strain of probiotics 
increases around the world, it will become easier to analyze and discuss the effect of 
probiotics. In addition, the effect of host microbial profiles was considered in this 
study; therefore, it is important to focus on these profiles, as well as changes to the 
host environment. 
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Chapter 3 
3. Molecular approaches for understanding 
murinal intestinal microbiota profiles 
3.1. Introduction 
Intestinal microbiota mainly refer to the bacteria inhabiting the intestinal tract of 
mammals; these bacteria support various functions in the host ranging from digestion 
to the maintenance of a robust immune function (Holmes et al., 2012). Recently, there 
have been many reports regarding the metabolites secreted by intestinal microbiota. 
For example, Japanese people possess specific bacteria that have the necessary gene 
for digesting laver and soft seaweed (Hehemann et al., 2010). Intestinal microbiota 
have also been reported in relation to host diseases such as obesity (Ridaura et al., 
2013; Turnbaugh et al., 2006), diabetes (Forslund et al., 2015; Le Chatelier et al., 2013; 
Qin et al., 2012), atherosclerosis (Koeth et al., 2013; Wang et al., 2011; 2016), atopic 
dermatitis (Björkstén et al., 1999; 2001; Kalliomäki et al., 2001), immune system 
disorders (Cahenzli et al., 2013; Thorburn et al., 2015), and brain function disorders 
(Buffington et al., 2016; Hsiao et al., 2013; Kadowaki et al., 2016; Sampson et al., 
2016). The human intestinal tract is a long organ, and microbial diversity is distinct 
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within each section of the intestinal tract and dependent on its corresponding function. 
In the case of humans, Lactobacillus accounts for a large percentage of microbes 
within the stomach, and Enterobacteriaceae spp. and Bacteroides are observed at high 
levels in the upper small intestine. In the lower small intestine, Bifidobacterium spp. 
and Enterococcus spp. exist at a high percentage. Additionally, Enterococcus spp. 
Enterobacteriaceae spp., Clostridium spp., and Bacteroides spp. are observed at a high 
percentage within the cecum and colon (Metges, 2000). Although there are many 
reports focused on the differences among varying parts of the intestine, these reports 
primarily focused on the stomach, cecum and colon or only included information 
solely about either the metabolite or microbial profile (Devaraj et al., 2013; Gu et al., 
2013; Matsumoto et al., 2012; Tian et al., 2012). In reports that focused on the 
intestinal differences with regard to location, pyrosequencing was used to evaluate the 
differences in intestinal contents derived from the stomach, the three parts of the small 
intestine, the cecum, the colon and fecal samples. However, metabolome profiling 
throughout the gastrointestinal tract has not been conducted. Therefore, in this study, 
we performed luminal metabolic evaluation for each section of the intestinal tract to 
understand the differences among each part of intestinal tract. We measured 
gastrointestinal luminal metabolites across different parts of the intestinal tract in 
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specific-pathogen-free (SPF) and germ-free (GF) mice using capillary electrophoresis 
time-of-flight mass spectrometry (CE-TOFMS) and liquid chromatography-tandem 
mass spectrometry (LC-MS/MS). 
 
3.2. Material and Methods 
3.2.1. Experimental design 
The animal experiment was performed using protocols approved by Central Institute 
for Experimental Animals (CIEA) (Tokyo, Japan). Germ-free (GF) male C57BL/6J 
mice and specific pathogen-free (SPF) male mice were purchased from CIEA Japan 
Inc. These GF mice were maintained in germ-free isolators at CIEA during experiment. 
GF and SPF mice were housed individually in each cage and fed with normal diet (CA-
1, CIEA Japan) ad libitum. Diet and water were both irradiated and autoclaved. Ethics 
numbers were 09043 and 12036. 
 
3.2.2. Sample collection and preparation for metabolome analysis 
Twelve-week-old male GF and SPF mice (n=3) were sacrificed for resecting intestinal 
contents via an abdominal incision. The intestinal tract was separated into six parts; 
stomach (St), upper small intestine (Si1), lower small intestine (Si2), cecum (Ce), 
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upper colon (Co1) and lower colon (Co2) (Figure 3.1). Intestinal contents were stored 
at -80°C until use. Extraction for intestinal metabolites was as described previously 
with slight modifications (Nagao-Kitamoto et al., 2016). Intestinal contents were run 
with 1 mL of 0.957 mM PBS contained 200 mM of internal standards (methionine 
sulfone and D-camphor-10-sulfonic acid) for metabolome analysis by using syringe. 
500 µL of sample solution was mixed with 500 µL of 100% methanol, then vortexed 
with 100 mg of 0.1 mm zirconia beads. The contents were centrifuged at 14,000 g for 
5 min. Supernatant was transferred to a centrifugal filter tube (UltrafreeMC-PLHCC 
250/pk for Metabolome Analysis, Human Metabolome Technologies) to remove 
protein and lipid molecules, and then centrifuged at 4,600 x g for 3 hours at 25 °C. 
Filtrates were centrifugally concentrated and dissolved in 30 µL of ultrapure water 
including reference compounds (200 µM each of 3-aminopyrrolidine and trimesic 
acid) immediately before capillary electrophoresis with electrospray ionization CE-
TOFMS analysis. Concentrations of sugars in samples were determined by LC-
MS/MS in negative multiple reaction monitoring mode on an API3000 triple 
quadrupole mass spectrometer (AB Sciex). All of LC-MS/MS data were acquired 
using Analyst Software (AB Sciex). 
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Figure 3.1 Collected sample position of gastrointestinal tract 
Intestinal tract was separated some parts. Samples were obtained from colored parts. Red and blue 
indicate SPF and GF mice, respectively. Left side shows head and right side shows tail. St: stomach, 
Si1: upper small intestine, Si2: lower small intestine, Ce: cecum, Co1: upper colon, Co2: lower 
colon. 
  
Head Tail
St Co1CeSi1 Si2 Co2
St Co1CeSi1 Si2 Co2
SPF
GF
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3.2.3. Instrument parameters for CE-TOFMS 
Metabolome analysis was conducted as described previously with some modifications 
(Sugimoto et al., 2010). All CE-TOFMS experiments were based on Agilent CE 
capillary electrophoresis system (Agilent Technologies, Waldbronn, Germany), an 
Agilent G3250 AA LS/MSD TOF system (Agilent Technologies, Palo Alto, CA), an 
Agilent 1100 series binary HPLC pump which delivers sheath liquid, a G1603A 
Agilent CE–MS adapter kit, and a G1607A Agilent CE-ESI-MS sprayer kit (Agilent 
Technologies, Waldbronn, Germany). The CE-MS adapter kit included a capillary 
cassette that facilitates thermostatting of the capillary. The CE-ESI-MS sprayer kit 
simplifies the connecting CE system and the MS system, which were equipped with 
an electrospray ionization source. For system control and data acquisition, G2201AA 
Agilent Chem-Station software for CE and Analyst QS software for TOFMS were 
used. 
 
3.2.4. LC-MS/MS Conditions 
The mobile phase consisted of 0.5% (v/v) formic acid as solution A and acetonitrile as 
solution B. The gradient increased from 0% B to 99% for taking 20 minutes and then 
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retained at 99% until 23 minutes. The flow rate used was 0.2 ml/min and the injection 
volume was 1 µl as described previously (Sugimoto et al., 2012). 
 
3.2.5. CE-TOFMS Conditions 
The CE-TOFMS conditions were as described previously with slight modification 
(Sugimoto et al., 2010). In the case of anionic metabolites, a commercially available 
COSMO(+) capillary (50 µm i.d. × 110 cm) (Nacalai Tesque, Kyoto, Japan), 
chemically coated with a cationic polymer, was used as the separation capillary. A 50 
mM ammonium acetate solution (pH 8.5) was the electrolyte for CE separation. A new 
capillary was flushed successively with the running electrolyte, 50 mmol/L acetic acid 
(pH 3.4), and then the electrolyte again for 10 min each. Before each injection, the 
capillary was equilibrated for 2 min by flushing with 50 mM acetic acid (pH 3.4) and 
then for 5 min by flushing with the running electrolyte. In the case of cationic 
metabolites, fused-silica capillaries (50 µm i.d. × 100 cm total length) filled with 1 
mol/L formic acid as the reference electrolyte was used as the separation capillary. 
After preparation the capillaries, sample solutions (30 nL) were injected at 50 mbar 
for 3 seconds, and a voltage of 30 kV, and −30 kV was applied. The capillary 
temperature was maintained at 20°C, and the temperature of the sample tray was kept 
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below 5°C. The sheath liquid, composed of methanol/water (50% v/v) and 0.1 µmol/L 
hexakis (2,2-difluoroethoxy) phosphazene (Hexakis), was delivered at 10 µL/min. 
ESI-TOF-MS was conducted in the positive ion mode and 5 mM ammonium acetate 
(50% v/v) methanol/water containing 0.1 µM Hexakis was derived at 10 µL/min in 
negative ion mode. The capillary voltage was set at 4 kV and 3500V, for cationic and 
anionic metabolites, respectively. In TOF-MS, the fragmenter, skimmer, and OCT RF 
voltage were set at 75, 50, and 125 V, respectively in positive ion mode, and at 100, 
50, and 200 V, respectively in negative ion mode. A flow rate of drying nitrogen gas 
(heater temperature = 300°C) was maintained at 10 L/min. In the case of positive ion 
mode, automatic recalibration of each acquired spectrum was performed using 
reference masses of reference standards ([13C isotopic ion of protonated methanol 
dimer (2MeOH + H)]+, m/z 66.06371) and ([protonated Hexakis (M + H)]+, m/z 
622.02896). In the case of negative ion mode, automatic recalibration of each acquired 
spectrum was performed using reference masses of reference standards ([13C isotopic 
ion of deprotonated acetic acid dimer (2CH3COOH - H)]-, m/z 120.03841), and 
([Hexakis + deprotonated acetic acid (CH3COOH - H)]-, m/z 680.03554). Exact mass 
data were acquired at a rate of 1.5 spectra/s over a m/z 50-1000 range. The alignment 
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of detected peaks was performed according to the m/z value and normalized migration 
time.  
 
3.2.6. Processing of metabolome data 
Raw data were analyzed with our proprietary software: MasterHands (Sugimoto et al., 
2010). Data were processed with noise-filtering, baseline correction, peak detection, 
and integration of the peak area from sliced electropherograms (m/z 0.02 width). 
Subsequently, the accurate m/z value for each peak detected within the time domain 
was calculated with Gaussian curve-fitting to the peak along the m/z axis. Spike noise, 
CE-specific noise showing small and narrow peaks, and low-quality (not peak-like 
shape) results were also removed. For the remaining features, metabolite identities 
were assigned by matching their m/z values and migration times with those of standard 
compounds. 
 
3.2.7. Metabolome data analysis 
SIMCA version 9.0.2 (SAS Institute, Cary, NC) and Multi Experiment Viewer (MeV 
TM4) (Saeed et al., 2003) were used for orthogonal projections to latent structures - 
discriminant analysis (OPLS-DA) and heat map analysis and clustering analysis and 
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K-means analysis, respectively. Metabolic pathway analysis was performed according 
to Kyoto Encyclopedia of Genes and Genomes (KEGG) and significant metabolites 
with p-value lesser than 0.1 were analyzed by MetaCore. 
 
3.2.8. DNA extraction, PCR amplification, and pyrosequencing of fecal samples 
DNA extraction was described as previously with slight modifications (Kato et al., 
2014). Freeze-dried fecal samples were homogenized with mixture buffer [200 µL 
10% SDS/TE, 200 µL 3M NaAc and 400µL phenol/chloroform/IAA] at 1,500 rpm for 
5 min at 4°C and then centrifuged at 14,000 rpm for 5 min at 4°C. After transferring 
supernatant into new tubes and adding 400 µL phenol chloroform/IAA and vortexed 
for 1 min. Samples were then centrifuged at 14,000 rpm for 10 min at 4°C. After 
transferring supernatant into new tubes again, 800 µL 100% EtOH was added and 
placed on ice for 15 min. The liquid was then centrifuged at 14,000 rpm for 5 min at 
4°C. The supernatant was discarded and 500 µL 70% EtOH was added to desiccate the 
pellet. The suspension was centrifuged at 14,000 rpm for 5 min at 4°C. The supernatant 
was then discarded and the pellet left to dry after which 100 µL TE was added and left 
at 4°C overnight. The V1-V2 region (310 bp) of 16S rRNA genes were amplified from 
genomic DNA samples using bacterial universal primer set 27F (5’-AGAGTTTGAT 
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CMTGGCTCAG-3’) and 338R (5’-TGCTGCCTCC CGTAGGAGT-3’) (Kim et al., 
2013; Murakami et al., 2015). PCR was performed with Tks Gflex DNA Polymerase 
(Takara Bio Inc.) and amplification proceeded with an initial denaturation step at 96°C 
for 2 min, followed by 15 or 20 cycles of 96°C for 30 sec, 55°C for 45 sec and 72°C 
for 1 min, with a final extension step at 72°C for 10 min. They were visualized on 
agarose gels (2% in TE Buffer), purified with a QIAamp PCR Purification Kit. Purified 
PCR products were tagged with unique barcode labels using forward primer (5’- 
CCATCTCATC CCTGCGTGTC TCCGACTCAG NNNNNNNNNN agagtttgat 
cmtggctcag -3’) containing the 454 primer A and reverse primer (5’- CCTATCCCCT 
GTGTGCCTTG GCAGTCTCAG tgctgcctcc cgtaggagt -3’) containing the 454 primer 
B by PCR reaction that was 2 min at 96°C, 5 cycles of 96°C for 30 s, 55°C for 45 s, 
and 72°C for 1min, and a final extension of 72°C for 10 min. Prior to sequencing, 454 
tagged PCR products were cleaned again with Agencourt AMPure XP (Beckman 
Coulter, Inc., Brea, CA, USA) and quantified using the Quant-iT PicoGreen DNA 
assay (Invitrogen, Carlsbad, CA). Following quantization, the amplicon from each 
reaction mixture were pooled in equimolar ratios based on concentration and subjected 
to emulsion PCR to generate amplicon libraries. Amplicon pyrosequencing was 
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performed on the Roche 454 GS Junior Titanium platform (Roche, Branford, CT, 
USA) according to the manufacturer’s specifications.  
 
3.2.9. Analysis of microbial 16S rRNA gene sequences 
Sequence reads with an average Q-value < 25 were filtered out. Reads were then 
processed using quantitative insights into microbial ecology (QIIME) (v1.8.0) pipeline 
(Caporaso et al., 2010). Sequences were then clustered into operational taxonomic 
units (OTUs) using 97% sequence similarity and OTUs were assigned to taxonomy 
using Ribosomal Database Project (RDP) classifier(Wang et al., 2007). 
 
3.2.10. Statistical analysis 
Statistical analysis was performed with MATLAB version R2015a (The MathWorks, 
Inc., United States). P-values < 0.05 were considered as statistically significant, with 
0.5 < p-value < 0.1 as the tendency. The correlation network based on Spearman’s 
correlation coefficient was constructed using R software. 
 
3.3. Results 
3.3.1. Characteristics of gastrointestinal luminal metabolites in SPF and GF mice 
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A metabolome analysis of gastrointestinal contents by CE-TOFMS and LC-MS/MS 
identified 344 and 308 metabolites, which were detected from SPF and GF mice, 
respectively (Figure 3.2). Additionally, 295, 269, 285, 300, 260, and 260 metabolites 
were detected in the stomach, upper small intestine, lower small intestine, cecum, 
upper colon and lower colon, respectively, from both SPF and GF mice (Figure 3.2). 
The numbers of metabolites were significantly different between SPF and GF mice in 
both the upper and lower colon (Figure 3.3). To visualize unique differences in 
metabolic data between GF and SPF mice, we performed principal component analysis 
(PCA). The PCA score plots were roughly separated by the presence of gut microbiota 
(Figure 3.4), suggesting that metabolites produced by gastrointestinal microbiota 
largely influence the luminal metabolome profile in each gastrointestinal section. 
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Figure 3.2 Luminal metabolome profiles of the gastrointestine  
in SPF and GF mice 
Venn diagram shows the number of detected identified gastrointestinal luminal metabolites in SPF 
and GF mice.   
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Figure 3.3 Differences of metabolites kinds in SPF and GF mice 
Bar shows the number of mean of detected gastrointestinal luminal metabolites in SPF and GF 
mice. Student's t test, *:p < 0.05, **:p < 0.001  
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Figure 3.4 PCA of gastrointestinal luminal metabolome profiles in SPF 
and GF mice. 
Error bars indicate standard deviation. Color designates the section of the intestinal tract, and shape 
denotes the type of mice used.  
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3.3.2.  Comparison of luminal metabolome profiles among each section of the 
gastrointestinal tracts 
To focus on features of the metabolome in each section of the gastrointestinal tract, 
we conducted K-means clustering based on z-score, and all metabolites in their 
respective clusters were categorized according to metabolic pathway designations 
from the KEGG database（Figure 3.5）. In SPF mice, each cluster indicates the specific 
features of the gastrointestinal organ. A subset of metabolites at the highest 
concentrations in the stomach was clustered as cluster A; stomach or upper and lower 
small intestine as cluster B; upper and lower small intestine as cluster C; lower small 
intestine as cluster D and cecum as cluster E. On the other hand, metabolites observed 
in GF mice were not separated clearly into the specific intestinal categories listed 
above for SPF mice. Metabolites from GF mice observed at the highest concentrations 
in the stomach and small intestine were clustered as cluster F and cluster G, 
respectively. Those metabolites with the highest concentrations in the upper small 
intestine and colon or cecum and colon were clustered as cluster H and cluster I, 
respectively, while metabolites observed at highest concentrations in the colon were 
clustered as cluster J. 
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 In the cecum and colon, the following metabolites—cholate, propionate, 
glucose, creatine and ribose—were detected at high concentrations only in SPF mice. 
Urea, inositol and dihydrouracil were detected only in GF mice. In the upper and lower 
small intestine, the numbers of identified metabolites were 32 and 58 in SPF mice and 
33 and 63 in GF mice, respectively (Figure 3.5 Cluster B, C, G and H). The kinds of 
metabolites identified were independent of the existence of microbiota. The type of 
metabolites identified in the cecum and colon was different from the type in the 
stomach and small intestine. The population of metabolites that participate in 
carbohydrate and amino acid metabolism were more variable among the different parts 
of the intestine compared with metabolites in other pathways. 
 Furthermore, in the case of SPF mice, the metabolites that were significantly 
different from GF mice have been suggested to be related to amino acid metabolism, 
in addition to nucleotide metabolism and its regulation, based on MetaCore analysis. 
In stomach and small intestine, the significantly different metabolites were related to 
the metabolism and regulation of amino acids such as glycine, serine, cysteine and 
threonine metabolism (Betaine, Choline, Dimethylglycine, Choline phosphate, 
Creatine, 5-amino-levulinic acid); taurine and hypotaurine metabolism (Taurine); 
beta-alanine metabolism (Beta-alanine); and arginine metabolism (Urea, 
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Guanidinoacetate, Creatine, Spermidine). In the cecum and upper colon of SPF mice, 
significantly altered metabolites, compared to GF mice, were related to nucleotide 
metabolism and its regulation, such as TTP metabolism (uracil, thymine, 2’-
deoxythymidine), CTP/UTP metabolism (Uridine, Uracil, Cytidine, Beta-alanine, 
UMP, CMP) and UMP biosynthesis (UMP). In the lower colon, significantly altered 
metabolites were related to amino acid metabolism and its regulation, such as 
Histidine-glutamate-glutamine metabolism (Urocanic acid, Succinic acid) and the 
tricarbonic acid cycle (Succinic acid). In the case of GF mice, few significant 
metabolites were detectable. In the stomach and upper small intestine, significant 
metabolites were related to nucleotide metabolism and its regulation, such as GTP-
XTP metabolism (guanosine, guanine) and dGTP metabolism (2’-deoxy-guanosine). 
In the lower small intestine, significant metabolites were related to nicotine action, 
such as nicotine metabolism in liver (S-Nornicotine). In the cecum and colon, 
significant metabolites were related to amino acid metabolism and its regulation, such 
as proline metabolism (4-Hydroxy-L-proline); arginine metabolism 
(Guanidinoacetate); and glycine, serine, cysteine and threonine metabolism 
(Guanidinoacetic acid). Although overlaps in metabolic pathways between SPF and 
GF mice were present, the differentiation in gastrointestinal location for specific 
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metabolites was different between the two types of mice, due to varying functions 
among gastrointestinal sections and gut microbiota colonization. 
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Figure 3.5 Differences in luminal metabolites among parts of the 
gastrointestinal tract in SPF and GF mice 
(A) Heatmap of luminal metabolites categorized into five groups using K-means analysis. Columns 
correspond to gastrointestinal sections, while rows correspond to metabolites detected by CE-
TOFMS and LC-MS/MS. Profiles were normalized to a relative value between -3 and 3. The colors 
indicate the z-score values calculated within SPF and GF mice separately. St: stomach, Si1: upper 
small intestine, Si2: lower small intestine, Ce: cecum, Co1: upper colon, Co2: lower colon. (B) 
Stack chart shows the percent distribution among pathways in which metabolites were detected 
within each cluster. 
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3.3.3. Comparison of gastrointestinal luminal metabolites between SPF and GF 
mice 
We conducted OPLS-DA on each part of the luminal metabolome profiles of both SPF 
and GF mice (Figure 3.6A). S-plots showed that some metabolites contributed to the 
separation between SPF and GF mice (Figure 3.6B,Table 3.1). The following 
concentrations of metabolites were higher in SPF mice than those in GF mice: taurine 
(81.9-fold in stomach, 7.2-fold in upper small intestine), lactate (7.7-fold in stomach, 
4.5-fold in upper colon), inositol (11.1-fold in stomach), maltose (811.0-fold in 
stomach), and butanoate (1374.2-fold in upper colon). Furthermore, taurine, butanoate 
and lactate appear to be characteristic metabolites within the upper small intestine, 
cecum, and upper colon, respectively, in SPF mice. On the other hand, raffinose 
(3680.3-fold in colon) was higher in the GF colon compared to that in the SPF colon. 
We conducted further microbiome analysis of the gastrointestine in SPF mice and 
found that microbiome profiles were distinctive among the differing parts of the 
gastrointestine (Figure 3.7). This result suggests that gastrointestinal luminal 
metabolome profiles may be related to the colonized microbiota, although further 
investigation is required to understand the detailed relationship between microbiota 
composition and metabolome profiles within the gastrointestinal tract of SPF mice. In 
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the case of unweighted, UniFrac analysis, the composition of gastrointestinal 
microbiota was similar within the same part of the intestine (Figure 3.7B) 
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Figure 3.6 OPLS-DA of the luminal metabolome profiles of the 
gastrointestine in SPF and GF mice 
(A) The result of OPLS-DA. Red and blue indicate SPF and GF mice, respectively. (B) S-plot for 
OPLS-DA o each section of the intestinal tract. Each model represented SPF and GF mice in a 
single location: the stomach, upper small intestine, lower small intestine, cecum, upper colon and 
lower colon, with the cross-validated predicted ability Q2(Y) = 1 and total explained variance 
R2(X) = 1, Q2(Y) = 0.96 and R2(X) = 0.93, Q2(Y) = 0.99 and R2(X) = 0.98, Q2(Y) = 0.99 and 
R2(X) = 0.89, Q2(Y) = 1 and R2(X) = 1, Q2(Y) = 1 and R2(X) = 1, respectively. 
  
3.Molecular approaches for understanding murinal intestinal microbiota profiles 
57 
Table 3.1 Characteristic luminal metabolites from each section of the 
gastrointestinal tract 
 GF side SPF side 
Metabolite x y Metabolite x y 
Stomach    
Maltose 
Lactate 
Inositol 
Taurine 
0.42 
0.35 
0.34 
0.33 
0.56 
0.89 
0.66 
0.93 
Upper small intestine    Taurine 0.32 0.98 
Lower small intestine       
Cecum    Butanoate 0.39 0.29 
0.97 
0.98 
Upper colon Raffinose -0.37 -0.88 Lactate 0.36 0.70 
Lower colon Raffinose -0.40 -1.00    
This table shows the characteristic luminal metabolites detected by S-plot. 
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Figure 3.7 Composition of gastrointestinal microbiota in SPF mice 
(A) Vertical bars indicate relative abundances of gastrointestinal microbiota colored by microbial 
family from binned OTU. Mice number was labeled at the bottom. St: stomach, Si1: upper small 
intestine, Si2: lower small intestine, Ce: cecum, Co1: upper colon, Co2: lower colon. (B) Principal 
coordinate analysis (PCoA) plot of sequence data. Left represents unweighted, and right represents 
weighted. 
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3.3.4. Features of sugars and amino acids within the gastrointestinal lumen of SPF 
and GF mice 
We measured the concentrations of 19 sugars and amino acids (Figure 3.9, Figure 
3.10). Sugars were separated into six groups using hierarchy clustering analysis to 
compare SPF and GF mice (Figure 3.9). These six categories displayed different 
metabolic patterns between each of the gastrointestinal locations. Panose was 
categorized as category A; this category includes metabolites observed at higher 
concentrations in the stomach of SPF mice compared to GF mice. Glucose, fructose, 
mannose and ribose were categorized as category B, which observed higher 
concentrations within the upper small intestine in SPF mice compared to GF mice. 
Mannitol, arabitol, sorbitol, raffinose, and trehalose were categorized as category C. 
The concentrations of these metabolites were higher within the upper colon in GF mice 
than concentrations in other GF gastrointestinal sections. Arabitol and trehalose had 
higher concentrations within the stomach and upper small intestine in SPF mice when 
compared with GF mice. In addition, category D includes inositol, maltotriose, sucrose, 
maltose and xylitol, which were more highly concentrated within the stomach in SPF 
mice when compared with GF mice. Categories E and F each included two metabolites, 
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galactose and rhamnose, and arabinose and xylose, respectively. These metabolites 
were all found to have high concentrations in the upper and lower colon in SPF mice.  
Amino acid profiles for each part of the gastrointestine between SPF and GF mice 
were drastically different (Figure 3.10). In SPF mice, the concentrations of all amino 
acids were higher in the upper gastrointestine than those of the lower intestine. 
However, in GF mice, the amino acid concentrations were higher in the lower intestine 
than those of the upper gastrointestine. From these findings, the amino acids are 
considered to be intermediate metabolites in both protein digestion and absorption by 
the host, as well as microbial digestion and metabolization of amino acids. 
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Figure 3.8 Clustered luminal carbohydrate profiles of the gastrointestine 
in SPF mice 
Carbohydrate profiles in SPF mice were clustered. St: stomach, Si1: upper small intestine, Si2: 
lower small intestine, Ce: cecum, Co1: upper colon, Co2: lower colon. These 6 clusters (the cut-
off height of 1.7 shown as red line) further clustered by hierarchy clustering analysis based on 
Pearson’s correlation. 
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Figure 3.9 Luminal carbohydrate profiles of the gastrointestine 
in SPF and GF mice 
Bar graphs indicate the average concentration of carbohydrate in gastrointestinal contents. Red and 
blue indicate SPF and GF mice, respectively. Error bars indicate standard error. St: stomach, Si1: 
upper small intestine, Si2: lower small intestine, Ce: cecum, Co1: upper colon, Co2: lower colon. 
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Figure 3.10 Luminal amino acid profiles of gastrointestine  
in SPF and GF mice 
Bar graphs indicate the average concentration of amino acids in gastrointestinal contents. Red and 
blue indicate SPF and GF mice, respectively. Error bars indicate standard error. St: stomach, Si1: 
upper small intestine, Si2: lower small intestine, Ce: cecum, Co1: upper colon, Co2: lower colon. 
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3.4. Discussion 
 The type and concentration of metabolites detected in this study were 
different between SPF and GF mice, although the quantity of identified metabolites 
was similar (Figure 3.2, Figure 3.3). PCA results showed that luminal metabolome 
profiles of SPF had higher diversity than GF mice (Figure 3.4). These differences seem 
to be dependent on the presence of microbiota. Cholate, propionate, glucose and ribose 
were detected only in SPF mice, while arabitol and trehalose were detected only in GF 
mice. Luminal metabolites were uniformly similar among each part of the intestinal 
tract in GF mice. On the other hand, some luminal metabolites were section-specific 
in the gastrointestinal tract of SPF mice, suggesting that these specific metabolites may 
be derived from gastrointestinal microbiota. In addition, PCA results showed that 
luminal metabolites in SPF and GF mice were categorized according to the location 
within the gastrointestinal tract (Figure 3.4). These profiles were expected due to the 
presence of gastrointestinal microbiota. When comparing luminal metabolome 
profiles between SPF and GF mice, higher amounts of organic acids, short-chain fatty 
acids (SCFA) and vitamins were detected in SPF mice (Table 3.1). Generally, it is well 
known that organic acids and SCFA are produced by intestinal microbiota (Furusawa 
et al., 2013; Matsumoto et al., 2012). 
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 Carbohydrate digestive enzymes such as amylase, saccharase, and maltase are 
mainly secreted in the small intestine. To further understand carbohydrate profiles 
throughout the gastrointestinal tract, we classified the carbohydrates detected in this 
study into six groups by hierarchy cluster analysis: (A) panose (B) glucose, fructose, 
mannose, ribose (C) mannitol, arabitol, sorbitol, raffinose, trehalose (D) maltose, 
maltotriose, sucrose, inositol, xylitol (E) galactose, rhamnose (F) arabinose, xylose 
(Figure 3.9). The metabolites identified at the highest concentration level within the 
stomach of SPF mice were categorized as either group A or D. Maltotriose, which was 
categorized in group D, is metabolized from amylose and starch (Quezada-Calvillo et 
al., 2007). Sucrose, which is also categorized in group D, is digested into glucose and 
fructose in the small intestine (Davidson and Leese, 1977). We predict that these group 
D metabolites were further digested in the upper gastrointestine by the host or 
microbiota, and then absorbed by host. As such, the Group D metabolites are not 
identified in the small intestine, cecum and colon. Group B consists of four 
monosaccharides detected at high levels in the upper small intestine of SPF mice; this 
outcome likely occurs because dietary food is digested in the stomach and then flows 
into the small intestine where it is absorbed there. Group C includes carbohydrates 
detected at higher concentrations in the lower intestine of GF mice than those of SPF 
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mice. Particularly, the concentrations of raffinose, sorbitol and mannitol were higher 
in the lower part of the colon in GF mice than those in SPF mice. It is estimated that 
these metabolites are accumulated in the upper colon because there are no bacteria 
present, and the host has little digestive use for them. Groups E and F contain four 
carbohydrates—arabinose, xylose, galactose and rhamnose—accumulated in the 
lower intestinal tract in SPF mice but are hardly produced in GF mice. In particular, 
the concentrations of arabinose, xylose and galactose gradually increased from the 
upper gastrointestinal tract to the lower in SPF mice. This result suggests that these 
metabolites were mainly produced from dietary food digestion by microbial 
carbohydrate enzymes and absorption by the small intestine may be difficult in mice.  
 Enzymes that digest protein, such as pepsin, trypsin, chymotrypsin and 
elastase, are secreted in the stomach and small intestine. Comparing the 
gastrointestinal luminal concentrations of the 20 amino acids detected in this study, 
we found that most amino acids profiles were similar (Figure 3.10), especially the 
finding of a relatively higher upper gastrointestinal tract concentration in SPF mice in 
opposition to those in GF mice. Based on these findings, we hypothesized that 
microbes contribute to protein digestion through their own protein digestive enzymes 
and/or enhance the secretion of protein digestion juice and enzymes from the host.  
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 In this study, we revealed the differences in gastrointestinal luminal 
metabolome profiles between GF and SPF mice and highlighted metabolic features 
from each section of the gastrointestinal tract. The types of metabolites and 
characteristic metabolisms were similar between SPF and GF mice, but the metabolite 
concentrations and profiles throughout the gastrointestinal tract were different. This 
outcome could be partially attributed to the differences in function among sections of 
the intestine but could also simply be due to the colonization of microbiota. 
Particularly, carbohydrate, amino acid, and SCFA profiles were drastically different 
between SPF and GF mice. Although further investigation is required for a complete 
understanding of the contribution of gut microbiota to gastrointestinal luminal 
metabolome profiles, our findings are a progressive step toward understanding the 
relationship between commensal microbiota and gastrointestinal luminal metabolites. 
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Chapter 4 
4. Conclusion 
I conducted two research studies in molecular biology and public health, 
aimed at understanding the intestinal microbiota with which we live. In the first study, 
clinical trials focused on the effects of probiotics on infant AD were systematically 
screened. The result of this meta-analysis showed that symptoms worsened when 
European children with AD consumed probiotics. It is difficult to discuss the effect of 
probiotics considering their variability, as well as the differing dynamics of microbial 
profiles, which proved to be a major limitation of this study. As the number of trials 
using the same strain of probiotics increases around the world, it will become easier to 
analyze and discuss the effect of probiotics. In addition, the effect of host microbial 
profiles was considered in this study; therefore, it is important to focus on these 
profiles, as well as changes to the host environment. In the second study, the difference 
of metabolomics profiles from various parts of the intestinal tract was evaluated. These 
metabolic profiles were also evaluated using GF and SPF mice to examine the effect 
of gut microorganisms. Similar types of metabolites were identified in both GF and 
SPF mice. 
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In these two studies, it is difficult to discuss the role and mechanisms of 
microbiota because of the complexity of the bacterial community. The intestinal 
microbiota form a complicated community composed of many types of bacteria. In the 
case of human intestines, it is known that E. coli colonizes first, followed by B. longum. 
Other species colonize subsequently in a step-by-step fashion (Mitsuoka, 1978). It 
remains unclear how the bacteria construct this robust community. It is important to 
understand the dynamics of intestinal microbiota, as well as the metabolites derived 
by them, to understand the ecosystem within our intestinal tract.  
Although details were not described here, I applied the method of a previous 
study (Stein et al., 2013) to this experimental data to simulate the dynamics of two 
kinds of intestinal microbes, E. coli and B. longum. Although some studies show the 
relationship between intestinal microbiota and metabolites, in addition to dynamics 
simulations of the bacterial community (Buffie et al., 2015; 2012; Coyte et al., 2015; 
Mishima et al., 2015), it is still unclear precisely how the dynamics of the bacteria and 
metabolites relate to one another. In addition, it is difficult to answer this question 
through a purely experimental approach.  
Two groups of mice were prepared for microbiota implantation, one where E. 
coli served as the initial infection and the other where B. longum served as the initial 
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infection (Figure 4.1). Four BALB/c male germ-free mice were used in each group. 
When the mice were 16 weeks old, they were infected by oral treatment with the initial 
microbial species, concentrated at 1.0×108 CFU, and the second microbial species 
were introduced 56 days following the initial infection. Professor Fukuda at Keio Univ. 
and Professor Ono’s group at RIKEN conducted this experiment. Five fecal samples 
were obtained at each of the following timepoints—0, 1, 2, 3, 6, 7, 14, 21, 28, 56, 57, 
58, 59, 62, 63, 70, 77, 84, and 112 days—for microbial and metabolic analysis. The 
microbial experimental data were obtained as described in Fukuda’s paper (Fukuda et 
al., 2011). 
  
4.Conclusion 
72 
 
Figure 4.1 Outline of experiment 
This figure presents the experiment. Samples were obtained at 0, 1, 2, 3, 6, 7, 14, 21, 28, 56, 57, 
58, 59, 62, 63, 70, 77, 84, and 112 days following initial infection. Microbial abundance data were 
not collected during the time frame enclosed within the gray area. 
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We used the Lotka-Volterra Model (LVM) as the basic equation. Microbial 
data were used for simulation, and then metabolic data were used to expand the 
generalized Lotka-Volterra equations. In this term, we explored how to simulate using 
only microbial data on MATLAB. The quantity of bacteria E and B are explained by 
growth rate (µE and µB), the effect from themselves (MEE and MBB), and the effect 
from other species (MEB and MBE) (Equations 1, 2). 
 
!"!# = 𝐸&" + 𝑀""𝐸) +𝑀"*𝐸𝐵 (1) !*!# = 𝐵&* +𝑀*"𝐵𝐸 + 𝑀**𝐵) (2) 
  
4.Conclusion 
74 
 
Figure 4.2 Result of modeling based on LVM 
The line shows the result of simulation based on the plotted experimental data. Blue and red 
indicate B.longum and E.coli, respectively. x: experimental data, o: geometric mean based on 
experimental data. 
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From this research, we found mathematical modeling to be a key tool in 
understanding the behavior of bacteria in the first term of the human infant microbiota. 
Although the Lotka-Volterra model could be built, the drop shown in this model at < 
5 days could not be explained using only microbial data (Figure 4.2). The results show 
that other such metabolites and immunoglobulins may have effects on the community 
among the bacteria. 
Concluding the results of this research, we explored the complicated 
environment of microbiota and related metabolites within a host. Further experimental 
and medical investigations are required to understand the intestinal environment, 
including metabolites and microbiota. In addition, some field persons need to 
collaborate for understanding the object. In case of probiotics, although the effects of 
probiotics is shown by a molecular biological research, it is difficult to show the same 
effect by meta-analysis in medical field. It happened because the practical research 
method is not enough to share among the related field person. If the importance meta-
analysis and any other methods is known by biological field researcher, the direction 
of research might be changed and become more effective research for other field and 
human. I hope researcher feel comfortable to collaborate with other field person and 
create the new values for themselves researches. 
References 
76 
Acknowledgements 
I would like to thank Prof. Masaru Tomita, the director of the Institute for Advanced 
Biosciences, Keio University (IAB), for providing an invaluable environment to 
execute my research. 
Dr. Shinji Fukuda, a Project Associated Professor in IAB, and Dr. Yumiko 
Nakanishi provided immense support for my research. Furthermore, I spent a great 
deal of time in Tsuruoka with Shinnosuke Murakami, Chiharu Ishii, and Keita 
Kamezaki enjoying student life. They have supported my research, even until midnight, 
and provided advice. 
Dr. Hitomi Sano taught me about modeling and simulations in the Doctoral 
course. I am thankful that she conveyed to me the importance of decision-making. Her 
words gave me a chance to make my decision. 
I enjoyed talking with Akane Nishigata, Hikaru Inoue, and Tsubasa Watabe, 
and these conversations made me comfortable and relaxed. Sometimes they heard my 
worries and attempted to understand my situation, for which I am thankful. 
Miho Tanaka, Shinkawa Haruka, Sayaka Saito, Yuriko Hasebe, Yuka Hirose, Hitoshi 
Iuchi, Megumi Uetaki, Mayuko Tsuruoka, Rena Fukuzawa, Fujitaka Baba, Haruka 
References 
77 
Oba, Kaori Yamamoto, Miyu Noguchi, Mayu Kotake, and Kanuka Tanaka made my 
life in Tsuruoka comfortable.  
Dr. Kazuharu Arakawa, Dr. Akio Kanai and Dr. Mitsuhiro Itaya provided 
useful words, which relayed many important things and encouraged me in my research.  
Ayumi Mikami, Mizukami, Aya Saito, Chisa Namba, Miho Sato, Maki Oike, 
Miwa Miramoto, and Satomi Yokoi assisted with important documents and 
administrations. 
The members of FC pharaoh and Spiber provided me with relaxation time in 
Tsuruoka. This time was important for me to refresh, in addition to the activities and 
exercise that kept me healthy. 
I give many thanks to my first adviser, Midori Hashimoto, for teaching me 
the first step of research. I learned many things from her: how to read papers and 
summarize research, the importance of attending conferences, and how to make 
progress. 
Dr. Toru Takebayashi and Dr. Daisuke Sugiyama taught me about public 
health and supported my master's thesis in the 2nd major. Midori Ishikawa and Miho 
Iida gave much advice. 
References 
78 
Dr. Joao Xavier, Hilary Monaco, Dr. Jonas, Karen Chu, Nathaniel Campbell, 
Silja Heilmann, Kerry Boyle, Carlos Carmona-Fontaine, Maxime Deforet, and 
Jinyuan Yan accepted me as a member of Xavier’s lab. They provided conversation 
and tried to help me think, even though my English was not perfect. Particularly, Dr. 
Xavier, Hilary and Jonas always conversed with me, providing many suggestions 
along with advice. These discussions were important for me to think about how to 
improve my research. 
Furthermore, I would like to thank the Program for Leading Graduate School 
for its ”Science for Development of Super Mature Society” in supporting my student 
life and research and teaching many things related to this world. My friends, Daisuke 
Ando, Takumi Kato, Masaki Sakamoto, Maki Dan, Hiroki Nagashima, Ken Nagao, 
Haoyang Yu, and Wataru Yoshiki gave me tremendous motivation for my research 
activities. I would further like to thank Prof. Dr. Fumihiko Kannari, Kenichi Hatori, 
Project Professor Masayuki Yamaguchi, and Project Professor Yoshiko Ishioka. 
Additionally, I would like to thank the members of this program for spending a great 
deal of time with me. 
I would like to thank Mimi Matsuki, Naoto Nishizaka, the team members, 
Akihiro Nakamura and colleagues at IBM, who always try to understand my situation 
References 
79 
and provide encouragement. Although managing work and being a student is hard, 
they understand and encourage me, making it possible to create a balance. 
Nao Mizoe is one of my best friends, and we spent much time together during 
her undergraduate training. She helped maintain my motivation through her 
undergraduate work. 
Hiroki Tanaka is special to me. He understood me and helped sustain my 
motivation. When I could not take it anymore, he gave me the chance to refresh. 
Sometimes, he persuaded me to face my research and taught me the methodology for 
simulation. Words cannot express how much I appreciate his kindness. 
Finally, I thank my family so much for supporting me in my student life, 
believing in me, and encouraging me. 
  
References 
80 
References 
Arumugam, M., Raes, J., Pelletier, E., Le Paslier, D., Yamada, T., Mende, D.R., Fernandes, 
G.R., Tap, J., Bruls, T., Batto, J.-M., et al. (2011). Enterotypes of the human gut 
microbiome. Nature 473, 174–180. 
Björkstén, B., Naaber, P., Sepp, E., and Mikelsaar, M. (1999). The intestinal microflora in 
allergic Estonian and Swedish 2-year-old children. Clin. Exp. Allergy 29, 342–346. 
Björkstén, B., Sepp, E., Julge, K., Voor, T., and Mikelsaar, M. (2001). Allergy development 
and the intestinal microflora during the first year of life. J. Allergy Clin. Immunol. 108, 
516–520. 
Buffie, C.G., Bucci, V., Stein, R.R., McKenney, P.T., Ling, L., Gobourne, A., No, D., Liu, H., 
Kinnebrew, M., Viale, A., et al. (2015). Precision microbiome reconstitution restores 
bile acid mediated resistance to Clostridium difficile. Nature 517, 205–208. 
Buffie, C.G., Jarchum, I., Equinda, M., Lipuma, L., Gobourne, A., Viale, A., Ubeda, C., 
Xavier, J., and Pamer, E.G. (2012). Profound alterations of intestinal microbiota 
following a single dose of clindamycin results in sustained susceptibility to Clostridium 
difficile-induced colitis. Infection and Immunity 80, 62–73. 
Buffington, S.A., Di Prisco, G.V., Auchtung, T.A., Ajami, N.J., Petrosino, J.F., and Costa-
Mattioli, M. (2016). Microbial Reconstitution Reverses Maternal Diet-Induced Social 
and Synaptic Deficits in Offspring. Cell 165, 1762–1775. 
Cahenzli, J., Köller, Y., Wyss, M., Geuking, M.B., and McCoy, K.D. (2013). Intestinal 
microbial diversity during early-life colonization shapes long-term IgE levels. Cell Host 
Microbe 14, 559–570. 
Caporaso, J.G., Kuczynski, J., Stombaugh, J., Bittinger, K., Bushman, F.D., Costello, E.K., 
Fierer, N., Peña, A.G., Goodrich, J.K., Gordon, J.I., et al. (2010). QIIME allows 
analysis of high-throughput community sequencing data. Nat. Methods 7, 335–336. 
Coyte, K.Z., Schluter, J., and Foster, K.R. (2015). The ecology of the microbiome: Networks, 
competition, and stability. Science 350, 663–666. 
Davidson, R.E., and Leese, H.J. (1977). Sucrose absorption by the rat small intestine in vivo 
and in vitro. J. Physiol. (Lond.) 267, 237–248. 
Devaraj, S., Hemarajata, P., and Versalovic, J. (2013). The human gut microbiome and body 
metabolism: implications for obesity and diabetes. Clin. Chem. 59, 617–628. 
Forslund, K., Hildebrand, F., Nielsen, T., Falony, G., Le Chatelier, E., Sunagawa, S., Prifti, 
E., Vieira-Silva, S., Gudmundsdottir, V., Pedersen, H.K., et al. (2015). Disentangling 
type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature 
528, 262–266. 
References 
81 
Fukuda, S., Toh, H., Hase, K., Oshima, K., Nakanishi, Y., Yoshimura, K., Tobe, T., Clarke, 
J.M., Topping, D.L., Suzuki, T., et al. (2011). Bifidobacteria can protect from 
enteropathogenic infection through production of acetate. Nature 469, 543–547. 
Fuller, R. (1989). Probiotics in man and animals. J. Appl. Bacteriol. 66, 365–378. 
Furusawa, Y., Obata, Y., Fukuda, S., Endo, T.A., Nakato, G., Takahashi, D., Nakanishi, Y., 
Uetake, C., Kato, K., Kato, T., et al. (2013). Commensal microbe-derived butyrate 
induces the differentiation of colonic regulatory T cells. Nature 504, 446–450. 
Gibson, G.R., and Roberfroid, M.B. (1995). Dietary modulation of the human colonic 
microbiota: introducing the concept of prebiotics. J. Nutr. 125, 1401–1412. 
Group, J.F.W.W. (2002). Guidelines for the evaluation of probiotics in food (London Ontario). 
Gu, S., Chen, D., Zhang, J.-N., Lv, X., Wang, K., Duan, L.-P., Nie, Y., and Wu, X.-L. (2013). 
Bacterial community mapping of the mouse gastrointestinal tract. PLoS ONE 8, e74957. 
Hehemann, J.-H., Correc, G., Barbeyron, T., Helbert, W., Czjzek, M., and Michel, G. (2010). 
Transfer of carbohydrate-active enzymes from marine bacteria to Japanese gut 
microbiota. Nature 464, 908–912. 
Hoffjan, S., and Stemmler, S. (2015). Unravelling the complex genetic background of atopic 
dermatitis: from genetic association results towards novel therapeutic strategies. Arch. 
Dermatol. Res. 307, 659–670. 
Holmes, E., Li, J.V., Marchesi, J.R., and Nicholson, J.K. (2012). Gut microbiota composition 
and activity in relation to host metabolic phenotype and disease risk. Cell Metab. 16, 
559–564. 
Hsiao, E.Y., McBride, S.W., Hsien, S., Sharon, G., Hyde, E.R., McCue, T., Codelli, J.A., 
Chow, J., Reisman, S.E., Petrosino, J.F., et al. (2013). Microbiota modulate behavioral 
and physiological abnormalities associated with neurodevelopmental disorders. Cell 
155, 1451–1463. 
Kadowaki, A., Miyake, S., Saga, R., Chiba, A., Mochizuki, H., and Yamamura, T. (2016). Gut 
environment-induced intraepithelial autoreactive CD4(+) T cells suppress central 
nervous system autoimmunity via LAG-3. Nature Communications 7, 11639. 
Kalliomäki, M., Kirjavainen, P., Eerola, E., Kero, P., Salminen, S., and Isolauri, E. (2001). 
Distinct patterns of neonatal gut microflora in infants in whom atopy was and was not 
developing. J. Allergy Clin. Immunol. 107, 129–134. 
Kato, T., Fukuda, S., Fujiwara, A., Suda, W., Hattori, M., Kikuchi, J., and Ohno, H. (2014). 
Multiple omics uncovers host-gut microbial mutualism during prebiotic 
fructooligosaccharide supplementation. DNA Res 21, 469–480. 
References 
82 
Kay, J., Gawkrodger, D.J., Mortimer, M.J., and Jaron, A.G. (1994). The prevalence of 
childhood atopic eczema in a general population. Journal of the American Academy of 
Dermatology 30, 35–39. 
Kim, S.-W., Suda, W., Kim, S., Oshima, K., Fukuda, S., Ohno, H., Morita, H., and Hattori, M. 
(2013). Robustness of gut microbiota of healthy adults in response to probiotic 
intervention revealed by high-throughput pyrosequencing. DNA Res 20, 241–253. 
Kim, S.-O., Ah, Y.-M., Yu, Y.M., Choi, K.H., Shin, W.-G., and Lee, J.-Y. (2014). Effects of 
probiotics for the treatment of atopic dermatitis: a meta-analysis of randomized 
controlled trials. Annals of Allergy, Asthma & Immunology 113, 217–226. 
Koeth, R.A., Wang, Z., Levison, B.S., Buffa, J.A., Org, E., Sheehy, B.T., Britt, E.B., Fu, X., 
Wu, Y., Li, L., et al. (2013). Intestinal microbiota metabolism of L-carnitine, a nutrient 
in red meat, promotes atherosclerosis. Nat. Med. 19, 576–585. 
Kostic, A.D., Howitt, M.R., and Garrett, W.S. (2013). Exploring host-microbiota interactions 
in animal models and humans. Genes & Development 27, 701–718. 
Le Chatelier, E., Nielsen, T., Qin, J., Prifti, E., Hildebrand, F., Falony, G., Almeida, M., 
Arumugam, M., Batto, J.-M., Kennedy, S., et al. (2013). Richness of human gut 
microbiome correlates with metabolic markers. Nature 500, 541–546. 
Lee, J., Yun, H.S., Cho, K.W., Oh, S., Kim, S.H., Chun, T., Kim, B., and Whang, K.Y. (2011). 
Evaluation of probiotic characteristics of newly isolated Lactobacillus spp.: Immune 
modulation and longevity. International Journal of Food Microbiology 148, 80–86. 
Leung, D.Y.M., and Bieber, T. (2003). Atopic dermatitis. Lancet 361, 151–160. 
Marsland, B.J., and Gollwitzer, E.S. (2014). Host-microorganism interactions in lung diseases. 
Nat. Rev. Immunol. 14, 827–835. 
Matsumoto, M., Kibe, R., Ooga, T., Aiba, Y., Kurihara, S., Sawaki, E., Koga, Y., and Benno, 
Y. (2012). Impact of intestinal microbiota on intestinal luminal metabolome. Sci Rep 2, 
233. 
Metges, C.C. (2000). Contribution of microbial amino acids to amino acid homeostasis of the 
host. J. Nutr. 130, 1857S–1864S. 
Mishima, E., Fukuda, S., Shima, H., Hirayama, A., Akiyama, Y., Takeuchi, Y., Fukuda, N.N., 
Suzuki, T., Suzuki, C., Yuri, A., et al. (2015). Alteration of the Intestinal Environment 
by Lubiprostone Is Associated with Amelioration of Adenine-Induced CKD. J. Am. 
Soc. Nephrol. 26, 1787–1794. 
Mitsuoka T. (1978). Chonai saikin no hanashi. Iwanami Shoten, Tokyo (in Japanese). 
Moher, D., Hopewell, S., Schulz, K.F., Montori, V., Gøtzsche, P.C., Devereaux, P.J., Elbourne, 
D., Egger, M., and Altman, D.G. (2010). CONSORT 2010 explanation and elaboration: 
updated guidelines for reporting parallel group randomised trials. Bmj 340, c869–c869. 
References 
83 
Murakami, S., Goto, Y., Ito, K., Hayasaka, S., Kurihara, S., Soga, T., Tomita, M., and Fukuda, 
S. (2015). The Consumption of Bicarbonate-Rich Mineral Water Improves Glycemic 
Control. Evid Based Complement Alternat Med 2015, 824395. 
Nagao-Kitamoto, H., Shreiner, A.B., Gillilland, M.G., Kitamoto, S., Ishii, C., Hirayama, A., 
Kuffa, P., El-Zaatari, M., Grasberger, H., Seekatz, A.M., et al. (2016). Functional 
Characterization of Inflammatory Bowel Disease-Associated Gut Dysbiosis in 
Gnotobiotic Mice. Cell Mol Gastroenterol Hepatol 2, 468–481. 
Qin, J., Li, Y., Cai, Z., Li, S., Zhu, J., Zhang, F., Liang, S., Zhang, W., Guan, Y., Shen, D., et 
al. (2012). A metagenome-wide association study of gut microbiota in type 2 diabetes. 
Nature 490, 55–60. 
Quezada-Calvillo, R., Robayo-Torres, C.C., Opekun, A.R., Sen, P., Ao, Z., Hamaker, B.R., 
Quaroni, A., Brayer, G.D., Wattler, S., Nehls, M.C., et al. (2007). Contribution of 
mucosal maltase-glucoamylase activities to mouse small intestinal starch alpha-
glucogenesis. J. Nutr. 137, 1725–1733. 
Ridaura, V.K., Faith, J.J., Rey, F.E., Cheng, J., Duncan, A.E., Kau, A.L., Griffin, N.W., 
Lombard, V., Henrissat, B., Bain, J.R., et al. (2013). Gut microbiota from twins 
discordant for obesity modulate metabolism in mice. Science 341, 1241214–1241214. 
Sacks, H.S., Berrier, J., and Reitman, D. (1987). Meta-analyses of randomized controlled trials. 
… England Journal of …. 
Saeed, A.I., Sharov, V., White, J., Li, J., Liang, W., Bhagabati, N., Braisted, J., Klapa, M., 
Currier, T., Thiagarajan, M., et al. (2003). TM4: a free, open-source system for 
microarray data management and analysis. BioTechniques 34, 374–378. 
Sampson, T.R., Debelius, J.W., Thron, T., Janssen, S., Shastri, G.G., Ilhan, Z.E., Challis, C., 
Schretter, C.E., Rocha, S., Gradinaru, V., et al. (2016). Gut Microbiota Regulate Motor 
Deficits and Neuroinflammation in a Model of Parkinson's Disease. Cell 167, 1469–
1480.e12. 
Schrezenmeir, J., and de Vrese, M. (2001). Probiotics, prebiotics, and synbiotics--approaching 
a definition. Am. J. Clin. Nutr. 73, 361S–364S. 
Smith, H.W. (1965). Observations on the flora of the alimentary tract of animals and factors 
affecting its composition. The Journal of Pathology and Bacteriology 89, 95–122. 
Stalder, J.F., and Taieb, A. (1993). Severity scoring of atopic dermatitis: the SCORAD index. 
Journal of Dermatological Science 6, 95. 
Stein, R.R., Bucci, V., Toussaint, N.C., Buffie, C.G., Rätsch, G., Pamer, E.G., Sander, C., and 
Xavier, J.B. (2013). Ecological modeling from time-series inference: insight into 
dynamics and stability of intestinal microbiota. PLoS Comput Biol 9, e1003388. 
References 
84 
Sugimoto, M., Kaneko, M., Onuma, H., Sakaguchi, Y., Mori, M., Abe, S., Soga, T., and 
Tomita, M. (2012). Changes in the charged metabolite and sugar profiles of pasteurized 
and unpasteurized Japanese sake with storage. J. Agric. Food Chem. 60, 2586–2593. 
Sugimoto, M., Wong, D.T., Hirayama, A., Soga, T., and Tomita, M. (2010). Capillary 
electrophoresis mass spectrometry-based saliva metabolomics identified oral, breast 
and pancreatic cancer-specific profiles. Metabolomics 6, 78–95. 
Thorburn, A.N., McKenzie, C.I., Shen, S., Stanley, D., Macia, L., Mason, L.J., Roberts, L.K., 
Wong, C.H.Y., Shim, R., Robert, R., et al. (2015). Evidence that asthma is a 
developmental origin disease influenced by maternal diet and bacterial metabolites. 
Nature Communications 6, 7320. 
Tian, Y., Zhang, L., Wang, Y., and Tang, H. (2012). Age-related topographical metabolic 
signatures for the rat gastrointestinal contents. J. Proteome Res. 11, 1397–1411. 
Turnbaugh, P.J., Ley, R.E., Mahowald, M.A., Magrini, V., Mardis, E.R., and Gordon, J.I. 
(2006). An obesity-associated gut microbiome with increased capacity for energy 
harvest. Nature 444, 1027–1031. 
Turroni, F., Peano, C., Pass, D.A., Foroni, E., Severgnini, M., Claesson, M.J., Kerr, C., 
Hourihane, J., Murray, D., Fuligni, F., et al. (2012). Diversity of Bifidobacteria within 
the Infant Gut Microbiota. PLoS ONE 7, e36957. 
Van Der Aa, L.B., Heymans, H.S., van Aalderen, W.M., Sillevis Smitt, J.H., Knol, J., Ben 
Amor, K., Goossens, D.A., Sprikkelman, A.B., Synbad Study Group (2010). Effect of 
a new synbiotic mixture on atopic dermatitis in infants: a randomized-controlled trial. 
Clin. Exp. Allergy 40, 795–804. 
Wang, Q., Garrity, G.M., Tiedje, J.M., and Cole, J.R. (2007). Naive Bayesian classifier for 
rapid assignment of rRNA sequences into the new bacterial taxonomy. Applied and 
Environmental Microbiology 73, 5261–5267. 
Wang, Z., Klipfell, E., Bennett, B.J., Koeth, R., Levison, B.S., Dugar, B., Feldstein, A.E., Britt, 
E.B., Fu, X., Chung, Y.-M., et al. (2011). Gut flora metabolism of phosphatidylcholine 
promotes cardiovascular disease. Nature 472, 57–63. 
Wang, Z., Roberts, A.B., Buffa, J.A., Levison, B.S., Zhu, W., Org, E., Gu, X., Huang, Y., 
Zamanian-Daryoush, M., Culley, M.K., et al. (2016). Non-lethal Inhibition of Gut 
Microbial Trimethylamine Production for the Treatment of Atherosclerosis. Cell 1–12. 
Won, T.J., Kim, B., Lee, Y., Bang, J.S., Oh, E.S., Yoo, J.-S., Hyung, K.E., Yoon, J., Hwang, 
S., Park, E.S., et al. (2012). Therapeutic potential of Lactobacillus plantarum CJLP133 
for house-dust mite-induced dermatitis in NC/Nga mice. Cellular Immunology 277, 49–
57. 
References 
85 
Won, T.J., Kim, B., Oh, E.S., Bang, J.S., Lee, Y.J., Yoo, J.-S., Yu, H., Yoon, J., Hyung, K.E., 
Park, S.-Y., et al. (2011). Immunomodulatory activity of Lactobacillus strains isolated 
from fermented vegetables and infant stool. Can. J. Physiol. Pharmacol. 89, 429–434.
Abbreviations 
86 
Abbreviations 
AA Amino Acids 
AD Atopic dermatitis 
bp Base pair 
CE-TOFMS Capillary electrophoresis with electrospray ionization time-of-flight mass spectrometry 
CFU Count-Forming Units 
CI Confidence interval 
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TE Tris- Ethylenediaminetetraacetic acid 
UMP Uridine 5'-monophosphate 
UTP Uridine triphosphate 
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